Table 1 |
||||||||||||
| Clinical profiles of the patients enrolled in this study | ||||||||||||
| No. | Sex | Diagnosis | Age of onset | Auto antibodies | Reason for adding TAC | On starting TAC | Complications ascribable to TAC | |||||
| Anti-Nuclear Antibody | Anti-Jo-1 Antibody | Disease duration (months) | Complications | MMT score | CK (IU/L) | Daily dosage of PSL (mg/day) | ||||||
| 1 | F | PM | 17 | - | - | DRP | 3 | - | 50 | 838 | 35 | - |
| 2 | F | PM | 37 | + | - | DRP | 4 | - | 53 | 775 | 30 | - |
| 3 | F | PM | 46 | - | - | DRP | 5 | - | 60 | 666 | 15 | - |
| 4 | M | PM | 55 | - | - | DRP | 5 | - | 60 | 482 | 15 | - |
| 6 | F | PM | 61 | - | - | DRP | 1 | - | 47 | 2241 | 45 | - |
| 7 | F | PM | 63 | - | - | DRP | 1 | - | 47 | 965 | 30 | - |
| 8 | F | PM | 37 | - | - | Recurrence | 180 | Osteoporosis, multiple rib fracture | 40 | 1809 | 2.5 | - |
| 9 | M | PM | 57 | - | - | Recurrence | 32 | Glaucoma | 60 | 810 | 4 | - |
| 10 | F | DM | 31 | - | + | DRP | 1 | - | 47 | 1665 | 50 | - |
| 11 | M | DM | 58 | - | - | DRP | 1 | - | 45 | 612 | 60 | - |
| 12 | F | DM | 59 | - | - | DRP | 1 | - | 35 | 3699 | 30 | - |
| 13 | F | DM | 60 | - | - | DRP | 1 | - | 35 | 3699 | 50 | - |
| 14 | F | DM | 72 | - | - | Recurrence | 8 | Osteoporosis | 35 | 864 | 20 | - |
| 15 | F | CADM | 24 | - | - | DRP | 1 | - | 60 | 74 | 25 | - |
CADM: clinically amyopathic dermatomyositis, CK: creatine kinase, DM: dermatomyositis, DRP: difficulty in reduction of prednisolone, MMT: manual muscle strength test, PSL: prednisolone, TAC: tacrolimus.
Shimojima et al. BMC Musculoskeletal Disorders 2012 13:228 doi:10.1186/1471-2474-13-228
